|Bid||174.20 x 800|
|Ask||174.60 x 900|
|Day's range||171.70 - 179.65|
|52-week range||85.65 - 236.17|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jul 2018 - 6 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||216.67|
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- – All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbA T87Q – – First Group C patient generating a normal total hemoglobin ...
Bluebird Bio's experimental gene therapy LentiGlobin is helping some patients with two life-threatening forms of inherited anemia avoid blood transfusions. In both sickle cell disorder and beta thalassemia, LentiGlobin raised levels of hemoglobin, the oxygen-carrying compound in the blood, to near-normal levels in some patients. Results from newer versions of LentiGlobin, which uses a virus to genetically modify a patient's own cells, outperformed earlier versions.
bluebird bio, Inc. (BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT.
bluebird bio, Inc. today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South ...
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy.
Bluebird Bio Inc. and Global Blood Therapeutics Inc. will be among biotechnology companies in the spotlight this week as doctors and investors flock to Stockholm for presentations at the Congress of European Hematology Association. Bluebird is expected to release data from its pivotal trial of LentiGlobin in patients with beta-thalassemia and updates on an earlier study of the therapy in patients with severe sickle cell disease. Competitor Global Blood will report updated data on its sickle cell treatment in patients ages 12 to 17, which analysts expect to have read-through to highly anticipated late-stage data in adults that are expected later this month.
Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. To access the live webcasts of bluebird bio’s presentations and conference calls, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.
Bluebird Bio Inc. shares lifted 9% in Monday morning trade after the company and its partner, Celgene Corp. , released phase 1 clinical trial results for the CAR-T cell therapy bb2121 showing that median patients survived for 11.8 months without their cancer progressing. Celgene shares declined 0.7%. The trial focused on patients with late-stage relapsed/refractory multiple myeloma, and patients had tried several other treatments before bb2121, with a median of seven prior myeloma treatment regimens.
The updates from ASCO can be practice-changing for doctors, life-changing for patients, and — for investors — market-moving.
In this article I am going to calculate the intrinsic value of bluebird bio Inc (NASDAQ:BLUE) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...
A treatment that genetically modifies a patient's own white blood cells to attack the cancer multiple myeloma had "impressive" results in an early clinical trial, experts say. The data are being presented at the annual meeting of the American Society of Clinical Oncology, the biggest convocation of cancer doctors. The treatment, codenamed bb2121 and being developed by Cambridge, Massachusetts-based Bluebird Bio and Summit, New Jersey-based Celgene, is a form of CAR-T, short for chimeric antigen receptor T-cell, for the type of white blood cell and the modifications made to it.
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESSWIRE)-- High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated ...
Celgene Corporation and bluebird bio, Inc. today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple myeloma.
Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.
David reviews why the Fool continues to recommend the volatile bluebird bio and why he invests in companies like it.
It's an especially motley show today: a little of this, a little of that, thoughts from an old show, a new essay, some borrowed wisdom, and a BLUE stock pick. And, hey, what's that in your shoe?
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
bluebird bio, Inc. (BLUE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder. Breakthrough Therapy designation is designed to expedite the development and review of a drug intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. “The founding of bluebird was inspired by the potential to develop a one-time gene therapy for boys suffering from this potentially fatal form of adrenoleukodystrophy,” said David Davidson, M.D., chief medical officer, bluebird bio.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
bluebird bio, Inc. announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent β-thalassemia and severe sickle cell disease will be highlighted in oral presentations at the 23rd Congress of the European Hematology Association .
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- - Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β ...
bluebird bio, Inc. announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.